For our client Resonance Health we have developed and currently market HepaFat-AI. HepFat-AI automatically analyses MRI datasets to assess liver fat in patients, providing doctors with a comprehensive, multi-metric solution for use in the assessment of individuals with confirmed or suspected fatty liver disease. From one quick, non-invasive MRI scan, doctors have access to a suite of metrics relating to a patient’s liver health. HepaFat-AI produces these patient results for clinician interpretation within seconds, providing accurate, reliable and reproducible results across MRI centres and scanner models. HepaFat-AI is ideally suited for single and multi-center clinical trials in non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). HepaFat-AI has received 510(k) clearance from the US Food and Drug Administration (FDA), European CE marking, and approval from the Australian Therapeutic Goods Administration (TGA).